Laboratory and clinical studies on roxithromycin in the treatment of chlamydial respiratory infections

Rinzo Soejima; Masashi Kimura; Yoshifumi Kubota; Toshio Kishimoto; Yoshihito Niki; Yoshihiko Tano; Toshiharu Matsushima; Tatsuo Nakatani; Kohichiro Nakata; Yoshiaki Kohri; Takekuni Iwata; Hiroko Nakajima; Masao Kuwabara; Ryoko Asaoku; Noriko Fukuhara; Masao Doi; Teruomi Miyazawa; Mitsuo Kaku; Hironori Tanaka; Hironobu Koga; Shigeru Kohno; Kohei Hara; Kohichi Watanabe; Takeshi Ishizaki; Naohumi Suyama; Seisin Nakano; Hidenori Sugiyama; Mutsushi Oka; Hozumi Yamada; Kaimei Nakahara; Masaya Yamaguchi; Yoichiro Goto; Toru Yamazaki; Hiroyuki Nagai; Hiroshi Kono; Masaru Nasu; Jun Goto; Kazuo Kitagawa; Eiichi Ohtsuka; Mitsunobu Akashi; Yoshinobu Kuroda; Eiji Yamagata; Hiroshi Nagaoka; Kaoru Nakama; Saburo Urakami; Hisashi Fukuhara; Yuei Irabu; Atsushi Saito; Hiroshi Nakamura; Masahiro Taira; Atsushi Ohhama; Yasuko Kanamoto

doi:10.11250/chemotherapy1953.42.877

Laboratory and clinical studies on roxithromycin in the treatment of chlamydial respiratory infections

Rinzo Soejima, Masashi Kimura, Yoshifumi Kubota, Toshio Kishimoto, Yoshihito Niki, Yoshihiko Tano, Toshiharu Matsushima, Tatsuo Nakatani, Kohichiro Nakata, Yoshiaki Kohri, Takekuni Iwata, Hiroko Nakajima, Masao Kuwabara, Ryoko Asaoku, Noriko Fukuhara, Masao Doi, Teruomi Miyazawa, Mitsuo Kaku, Hironori Tanaka, Hironobu KogaShigeru Kohno, Kohei Hara, Kohichi Watanabe, Takeshi Ishizaki, Naohumi Suyama, Seisin Nakano, Hidenori Sugiyama, Mutsushi Oka, Hozumi Yamada, Kaimei Nakahara, Masaya Yamaguchi, Yoichiro Goto, Toru Yamazaki, Hiroyuki Nagai, Hiroshi Kono, Masaru Nasu, Jun Goto, Kazuo Kitagawa, Eiichi Ohtsuka, Mitsunobu Akashi, Yoshinobu Kuroda, Eiji Yamagata, Hiroshi Nagaoka, Kaoru Nakama, Saburo Urakami, Hisashi Fukuhara, Yuei Irabu, Atsushi Saito, Hiroshi Nakamura, Masahiro Taira, Atsushi Ohhama, Yasuko Kanamoto

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

We studied the in vitro and in vivo activities of roxithromycin (RXM) against three species of Chlamydia, Chlamydia psittaci, Chlamydia trachomatis and Chlamydia pneumoniae, and compared its therapeutic efficacy against C. psittaci-induced pneumonia in mice with erythromycin, clarythromycin and minocycline. In addition, we studied the clinical efficacy of RXM in patients with chlamydial respiratory infection. The results were as follows: 1. Antibacterial activity: In vitro and in vivo activities of RXM against Chlamydiae were investigated. MICs of RXM against the strains of C. pneumoniae (TW-183, AR-39, AR-388 and our own isolate KKpn-1), C. psittaci (Budgerigar, California 10) and C. trachomatis (serobar D/UW-3/Cx) were 0.063 to 0.25 μg/ml, superior to those of erythromycin and ofloxacin, but inferior to those of minocycline and clarythromycin. In the therapeutic efficacy of RXM against experimental C. psittaci pneumonia, the survival rates of mice treated with RXM at 10 and 20 mg/kg twice daily for 7 days were 100% at 2 weeks after infection, while 0 −70% of the animals treated with EM survived. 2. Clinical efficacy and safety: RXM was administered orally to 19 patients with chlamydial respiratory infection at a dosage of 300 mg daily for 3 to 21 days, and clinical efficacy was evaluated in 14 cases. The Clinical efficacy was excellent in 2, good in 11 and fair in 1; the efficacy rate was 92.9% (13/14). As to side effects, abdominal pain and melena were observed in one case. As abnormal laboratory findings, the elevation of GOT and γ-GTP and the elevation of γ-GTP and total bilirubin were observed in one case each. These abnormalities were all mild and transient. From these results, we conclude that RXM is one of the most useful macrolide agents for chlamydial respiratory infections.

Original language	English
Pages (from-to)	877-889
Number of pages	13
Journal	Chemotherapy
Volume	42
Issue number	7
DOIs	https://doi.org/10.11250/chemotherapy1953.42.877
Publication status	Published - 1994
Externally published	Yes

Keywords

roxithromycin (RXM)

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.42.877

Cite this

Soejima, R., Kimura, M., Kubota, Y., Kishimoto, T., Niki, Y., Tano, Y., Matsushima, T., Nakatani, T., Nakata, K., Kohri, Y., Iwata, T., Nakajima, H., Kuwabara, M., Asaoku, R., Fukuhara, N., Doi, M., Miyazawa, T., Kaku, M., Tanaka, H., ... Kanamoto, Y. (1994). Laboratory and clinical studies on roxithromycin in the treatment of chlamydial respiratory infections. Chemotherapy, 42(7), 877-889. https://doi.org/10.11250/chemotherapy1953.42.877

Soejima, R, Kimura, M, Kubota, Y, Kishimoto, T, Niki, Y, Tano, Y, Matsushima, T, Nakatani, T, Nakata, K, Kohri, Y, Iwata, T, Nakajima, H, Kuwabara, M, Asaoku, R, Fukuhara, N, Doi, M, Miyazawa, T, Kaku, M, Tanaka, H, Koga, H, Kohno, S, Hara, K, Watanabe, K, Ishizaki, T, Suyama, N, Nakano, S, Sugiyama, H, Oka, M, Yamada, H, Nakahara, K, Yamaguchi, M, Goto, Y, Yamazaki, T, Nagai, H, Kono, H, Nasu, M, Goto, J, Kitagawa, K, Ohtsuka, E, Akashi, M, Kuroda, Y, Yamagata, E, Nagaoka, H, Nakama, K, Urakami, S, Fukuhara, H, Irabu, Y, Saito, A, Nakamura, H, Taira, M, Ohhama, A & Kanamoto, Y 1994, 'Laboratory and clinical studies on roxithromycin in the treatment of chlamydial respiratory infections', Chemotherapy, vol. 42, no. 7, pp. 877-889. https://doi.org/10.11250/chemotherapy1953.42.877

@article{6ebe69cbdebb4d849a2ef4276e70c170,

title = "Laboratory and clinical studies on roxithromycin in the treatment of chlamydial respiratory infections",

abstract = "We studied the in vitro and in vivo activities of roxithromycin (RXM) against three species of Chlamydia, Chlamydia psittaci, Chlamydia trachomatis and Chlamydia pneumoniae, and compared its therapeutic efficacy against C. psittaci-induced pneumonia in mice with erythromycin, clarythromycin and minocycline. In addition, we studied the clinical efficacy of RXM in patients with chlamydial respiratory infection. The results were as follows: 1. Antibacterial activity: In vitro and in vivo activities of RXM against Chlamydiae were investigated. MICs of RXM against the strains of C. pneumoniae (TW-183, AR-39, AR-388 and our own isolate KKpn-1), C. psittaci (Budgerigar, California 10) and C. trachomatis (serobar D/UW-3/Cx) were 0.063 to 0.25 μg/ml, superior to those of erythromycin and ofloxacin, but inferior to those of minocycline and clarythromycin. In the therapeutic efficacy of RXM against experimental C. psittaci pneumonia, the survival rates of mice treated with RXM at 10 and 20 mg/kg twice daily for 7 days were 100% at 2 weeks after infection, while 0 −70% of the animals treated with EM survived. 2. Clinical efficacy and safety: RXM was administered orally to 19 patients with chlamydial respiratory infection at a dosage of 300 mg daily for 3 to 21 days, and clinical efficacy was evaluated in 14 cases. The Clinical efficacy was excellent in 2, good in 11 and fair in 1; the efficacy rate was 92.9% (13/14). As to side effects, abdominal pain and melena were observed in one case. As abnormal laboratory findings, the elevation of GOT and γ-GTP and the elevation of γ-GTP and total bilirubin were observed in one case each. These abnormalities were all mild and transient. From these results, we conclude that RXM is one of the most useful macrolide agents for chlamydial respiratory infections.",

keywords = "roxithromycin (RXM)",

author = "Rinzo Soejima and Masashi Kimura and Yoshifumi Kubota and Toshio Kishimoto and Yoshihito Niki and Yoshihiko Tano and Toshiharu Matsushima and Tatsuo Nakatani and Kohichiro Nakata and Yoshiaki Kohri and Takekuni Iwata and Hiroko Nakajima and Masao Kuwabara and Ryoko Asaoku and Noriko Fukuhara and Masao Doi and Teruomi Miyazawa and Mitsuo Kaku and Hironori Tanaka and Hironobu Koga and Shigeru Kohno and Kohei Hara and Kohichi Watanabe and Takeshi Ishizaki and Naohumi Suyama and Seisin Nakano and Hidenori Sugiyama and Mutsushi Oka and Hozumi Yamada and Kaimei Nakahara and Masaya Yamaguchi and Yoichiro Goto and Toru Yamazaki and Hiroyuki Nagai and Hiroshi Kono and Masaru Nasu and Jun Goto and Kazuo Kitagawa and Eiichi Ohtsuka and Mitsunobu Akashi and Yoshinobu Kuroda and Eiji Yamagata and Hiroshi Nagaoka and Kaoru Nakama and Saburo Urakami and Hisashi Fukuhara and Yuei Irabu and Atsushi Saito and Hiroshi Nakamura and Masahiro Taira and Atsushi Ohhama and Yasuko Kanamoto",

year = "1994",

doi = "10.11250/chemotherapy1953.42.877",

language = "English",

volume = "42",

pages = "877--889",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "7",

}

TY - JOUR

T1 - Laboratory and clinical studies on roxithromycin in the treatment of chlamydial respiratory infections

AU - Soejima, Rinzo

AU - Kimura, Masashi

AU - Kubota, Yoshifumi

AU - Kishimoto, Toshio

AU - Niki, Yoshihito

AU - Tano, Yoshihiko

AU - Matsushima, Toshiharu

AU - Nakatani, Tatsuo

AU - Nakata, Kohichiro

AU - Kohri, Yoshiaki

AU - Iwata, Takekuni

AU - Nakajima, Hiroko

AU - Kuwabara, Masao

AU - Asaoku, Ryoko

AU - Fukuhara, Noriko

AU - Doi, Masao

AU - Miyazawa, Teruomi

AU - Kaku, Mitsuo

AU - Tanaka, Hironori

AU - Koga, Hironobu

AU - Kohno, Shigeru

AU - Hara, Kohei

AU - Watanabe, Kohichi

AU - Ishizaki, Takeshi

AU - Suyama, Naohumi

AU - Nakano, Seisin

AU - Sugiyama, Hidenori

AU - Oka, Mutsushi

AU - Yamada, Hozumi

AU - Nakahara, Kaimei

AU - Yamaguchi, Masaya

AU - Goto, Yoichiro

AU - Yamazaki, Toru

AU - Nagai, Hiroyuki

AU - Kono, Hiroshi

AU - Nasu, Masaru

AU - Goto, Jun

AU - Kitagawa, Kazuo

AU - Ohtsuka, Eiichi

AU - Akashi, Mitsunobu

AU - Kuroda, Yoshinobu

AU - Yamagata, Eiji

AU - Nagaoka, Hiroshi

AU - Nakama, Kaoru

AU - Urakami, Saburo

AU - Fukuhara, Hisashi

AU - Irabu, Yuei

AU - Saito, Atsushi

AU - Nakamura, Hiroshi

AU - Taira, Masahiro

AU - Ohhama, Atsushi

AU - Kanamoto, Yasuko

PY - 1994

Y1 - 1994

N2 - We studied the in vitro and in vivo activities of roxithromycin (RXM) against three species of Chlamydia, Chlamydia psittaci, Chlamydia trachomatis and Chlamydia pneumoniae, and compared its therapeutic efficacy against C. psittaci-induced pneumonia in mice with erythromycin, clarythromycin and minocycline. In addition, we studied the clinical efficacy of RXM in patients with chlamydial respiratory infection. The results were as follows: 1. Antibacterial activity: In vitro and in vivo activities of RXM against Chlamydiae were investigated. MICs of RXM against the strains of C. pneumoniae (TW-183, AR-39, AR-388 and our own isolate KKpn-1), C. psittaci (Budgerigar, California 10) and C. trachomatis (serobar D/UW-3/Cx) were 0.063 to 0.25 μg/ml, superior to those of erythromycin and ofloxacin, but inferior to those of minocycline and clarythromycin. In the therapeutic efficacy of RXM against experimental C. psittaci pneumonia, the survival rates of mice treated with RXM at 10 and 20 mg/kg twice daily for 7 days were 100% at 2 weeks after infection, while 0 −70% of the animals treated with EM survived. 2. Clinical efficacy and safety: RXM was administered orally to 19 patients with chlamydial respiratory infection at a dosage of 300 mg daily for 3 to 21 days, and clinical efficacy was evaluated in 14 cases. The Clinical efficacy was excellent in 2, good in 11 and fair in 1; the efficacy rate was 92.9% (13/14). As to side effects, abdominal pain and melena were observed in one case. As abnormal laboratory findings, the elevation of GOT and γ-GTP and the elevation of γ-GTP and total bilirubin were observed in one case each. These abnormalities were all mild and transient. From these results, we conclude that RXM is one of the most useful macrolide agents for chlamydial respiratory infections.

AB - We studied the in vitro and in vivo activities of roxithromycin (RXM) against three species of Chlamydia, Chlamydia psittaci, Chlamydia trachomatis and Chlamydia pneumoniae, and compared its therapeutic efficacy against C. psittaci-induced pneumonia in mice with erythromycin, clarythromycin and minocycline. In addition, we studied the clinical efficacy of RXM in patients with chlamydial respiratory infection. The results were as follows: 1. Antibacterial activity: In vitro and in vivo activities of RXM against Chlamydiae were investigated. MICs of RXM against the strains of C. pneumoniae (TW-183, AR-39, AR-388 and our own isolate KKpn-1), C. psittaci (Budgerigar, California 10) and C. trachomatis (serobar D/UW-3/Cx) were 0.063 to 0.25 μg/ml, superior to those of erythromycin and ofloxacin, but inferior to those of minocycline and clarythromycin. In the therapeutic efficacy of RXM against experimental C. psittaci pneumonia, the survival rates of mice treated with RXM at 10 and 20 mg/kg twice daily for 7 days were 100% at 2 weeks after infection, while 0 −70% of the animals treated with EM survived. 2. Clinical efficacy and safety: RXM was administered orally to 19 patients with chlamydial respiratory infection at a dosage of 300 mg daily for 3 to 21 days, and clinical efficacy was evaluated in 14 cases. The Clinical efficacy was excellent in 2, good in 11 and fair in 1; the efficacy rate was 92.9% (13/14). As to side effects, abdominal pain and melena were observed in one case. As abnormal laboratory findings, the elevation of GOT and γ-GTP and the elevation of γ-GTP and total bilirubin were observed in one case each. These abnormalities were all mild and transient. From these results, we conclude that RXM is one of the most useful macrolide agents for chlamydial respiratory infections.

KW - roxithromycin (RXM)

UR - http://www.scopus.com/inward/record.url?scp=0027984844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027984844&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.42.877

DO - 10.11250/chemotherapy1953.42.877

M3 - Article

AN - SCOPUS:0027984844

VL - 42

SP - 877

EP - 889

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

IS - 7

ER -

Laboratory and clinical studies on roxithromycin in the treatment of chlamydial respiratory infections

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this